FY2025 Earnings Forecast for ARWR Issued By B. Riley

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at B. Riley issued their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Monday, August 11th. B. Riley analyst M. El-Saadi expects that the biotechnology company will post earnings of $0.82 per share for the year. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.69 EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at ($2.09) EPS and FY2029 earnings at $0.46 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $29.01 million. During the same quarter last year, the business posted ($1.38) EPS.

ARWR has been the topic of several other reports. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada dropped their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 12.3%

Shares of ARWR stock opened at $19.99 on Wednesday. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $27.34. The stock’s fifty day moving average price is $16.59 and its 200 day moving average price is $15.95. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -15.62 and a beta of 0.94.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after buying an additional 1,018,273 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 25.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company’s stock valued at $208,889,000 after buying an additional 2,222,223 shares during the period. Slate Path Capital LP lifted its holdings in shares of Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company’s stock valued at $98,362,000 after buying an additional 347,000 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after buying an additional 28,193 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.